Targets › IDUA
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Jan 2035.
Lysosomal hydrolase responsible for the degradation of the glycosaminoglycans heparan sulfate and dermatan sulfate. (UniProt, P35475)
Open in Phaseline: the race on IDUA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Orchard Therapeutics | Autologous CD34+ hematopoietic stem and progenitor cells genetically modified wi Lentiviral vector-mediated gene therapy delivering human α-L-iduronidase (IDUA) cDNA to au | IDUA | Phase 1 | Mucopolysaccharidosis IH | Jan 2035 |
Mucopolysaccharidosis IH (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.